252 related articles for article (PubMed ID: 37978129)
1. Mechanisms of PARP Inhibitor Resistance.
O'Connor MJ; Forment JV
Cancer Treat Res; 2023; 186():25-42. PubMed ID: 37978129
[TBL] [Abstract][Full Text] [Related]
2. Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance.
Serra V; Wang AT; Castroviejo-Bermejo M; Polanska UM; Palafox M; Herencia-Ropero A; Jones GN; Lai Z; Armenia J; Michopoulos F; Llop-Guevara A; Brough R; Gulati A; Pettitt SJ; Bulusu KC; Nikkilä J; Wilson Z; Hughes A; Wijnhoven PWG; Ahmed A; Bruna A; Gris-Oliver A; Guzman M; Rodríguez O; Grueso J; Arribas J; Cortés J; Saura C; Lau A; Critchlow S; Dougherty B; Caldas C; Mills GB; Barrett JC; Forment JV; Cadogan E; Lord CJ; Cruz C; Balmaña J; O'Connor MJ
Clin Cancer Res; 2022 Oct; 28(20):4536-4550. PubMed ID: 35921524
[TBL] [Abstract][Full Text] [Related]
3. Current and future landscape of poly (ADP-ribose) polymerase inhibition resistance.
Hinchcliff E; Chelariu-Raicu A; Westin SN
Curr Opin Obstet Gynecol; 2021 Feb; 33(1):19-25. PubMed ID: 33315700
[TBL] [Abstract][Full Text] [Related]
4. The Clinical Challenges, Trials, and Errors of Combatting Poly(ADP-Ribose) Polymerase Inhibitors Resistance.
Pham MM; Hinchcliff E; Avila M; Westin SN
Cancer J; 2021 Nov-Dec 01; 27(6):491-500. PubMed ID: 34904812
[TBL] [Abstract][Full Text] [Related]
5. Resistance to Poly (ADP-Ribose) Polymerase Inhibitors (PARPi): Mechanisms and Potential to Reverse.
Washington CR; Moore KN
Curr Oncol Rep; 2022 Dec; 24(12):1685-1693. PubMed ID: 36346509
[TBL] [Abstract][Full Text] [Related]
6. PARP inhibitor resistance: the underlying mechanisms and clinical implications.
Li H; Liu ZY; Wu N; Chen YC; Cheng Q; Wang J
Mol Cancer; 2020 Jun; 19(1):107. PubMed ID: 32563252
[TBL] [Abstract][Full Text] [Related]
7. Cell cycle checkpoints and beyond: Exploiting the ATR/CHK1/WEE1 pathway for the treatment of PARP inhibitor-resistant cancer.
Gupta N; Huang TT; Horibata S; Lee JM
Pharmacol Res; 2022 Apr; 178():106162. PubMed ID: 35259479
[TBL] [Abstract][Full Text] [Related]
8. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
Lau CH; Seow KM; Chen KH
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
[TBL] [Abstract][Full Text] [Related]
9. Tackling PARP inhibitor resistance.
Fugger K; Hewitt G; West SC; Boulton SJ
Trends Cancer; 2021 Dec; 7(12):1102-1118. PubMed ID: 34563478
[TBL] [Abstract][Full Text] [Related]
10. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.
Haynes B; Murai J; Lee JM
Cancer Treat Rev; 2018 Dec; 71():1-7. PubMed ID: 30269007
[TBL] [Abstract][Full Text] [Related]
11. Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models.
Kim H; Xu H; George E; Hallberg D; Kumar S; Jagannathan V; Medvedev S; Kinose Y; Devins K; Verma P; Ly K; Wang Y; Greenberg RA; Schwartz L; Johnson N; Scharpf RB; Mills GB; Zhang R; Velculescu VE; Brown EJ; Simpkins F
Nat Commun; 2020 Jul; 11(1):3726. PubMed ID: 32709856
[TBL] [Abstract][Full Text] [Related]
12. Developing patient-derived organoids to predict PARP inhibitor response and explore resistance overcoming strategies in ovarian cancer.
Tao M; Sun F; Wang J; Wang Y; Zhu H; Chen M; Liu L; Liu L; Lin H; Wu X
Pharmacol Res; 2022 May; 179():106232. PubMed ID: 35462012
[TBL] [Abstract][Full Text] [Related]
13. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
[TBL] [Abstract][Full Text] [Related]
14. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.
Yazinski SA; Comaills V; Buisson R; Genois MM; Nguyen HD; Ho CK; Todorova Kwan T; Morris R; Lauffer S; Nussenzweig A; Ramaswamy S; Benes CH; Haber DA; Maheswaran S; Birrer MJ; Zou L
Genes Dev; 2017 Feb; 31(3):318-332. PubMed ID: 28242626
[TBL] [Abstract][Full Text] [Related]
15. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.
Cerrato A; Morra F; Celetti A
J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198
[TBL] [Abstract][Full Text] [Related]
16. PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies.
Miller RE; El-Shakankery KH; Lee JY
J Gynecol Oncol; 2022 May; 33(3):e44. PubMed ID: 35320891
[TBL] [Abstract][Full Text] [Related]
17. The role of patient-derived ovarian cancer organoids in the study of PARP inhibitors sensitivity and resistance: from genomic analysis to functional testing.
Tao M; Wu X
J Exp Clin Cancer Res; 2021 Oct; 40(1):338. PubMed ID: 34702316
[TBL] [Abstract][Full Text] [Related]
18. Distinct roles of treatment schemes and BRCA2 on the restoration of homologous recombination DNA repair and PARP inhibitor resistance in ovarian cancer.
Huang TT; Burkett SS; Tandon M; Yamamoto TM; Gupta N; Bitler BG; Lee JM; Nair JR
Oncogene; 2022 Nov; 41(46):5020-5031. PubMed ID: 36224341
[TBL] [Abstract][Full Text] [Related]
19. Clinical Application of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Ovarian Cancer.
Pham MM; Avila M; Hinchcliff E; Westin SN
Cancer Treat Res; 2023; 186():71-89. PubMed ID: 37978131
[TBL] [Abstract][Full Text] [Related]
20. Appropriate Selection of PARP Inhibitors in Ovarian Cancer.
Smith M; Pothuri B
Curr Treat Options Oncol; 2022 Jun; 23(6):887-903. PubMed ID: 35412195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]